Zydus Cadila gets tentative approval from USFDA for Empagliflozin Tablets

11 Apr 2020 Evaluate

Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Empagliflozin Tablets, in the strengths of 10 mg and 25 mg. The medication is used together with diet and exercise to improve blood sugar control in adults with Type 2 diabetes mellitus. It is also used to reduce the risk of cardiovascular death in adult patients with Type 2 diabetes mellitus and established cardiovascular disease.

The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad. The group now has 286 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

907.60 -19.60 (-2.11%)
08-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1761.45
Dr. Reddys Lab 1207.50
Cipla 1460.60
Zydus Lifesciences 907.60
Lupin 2190.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×